MTOR and renal cell carcinoma: (Figure 2ce) comparable to the effect of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus, an effective targeted treatment used clinically in metastatic RCC patients [35], in 786-O-bearing mice [36].